Related Experiment Video
Updated: Jul 8, 2025
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.3K
Summary
A new drug, avasopasem manganese, may allow higher radiation doses for pancreatic cancer. Early results suggest improved outcomes when combined with stereotactic body radiation therapy.
Area of Science:
- Oncology
- Radiation Oncology
- Pharmacology
Background:
- Pancreatic cancer is a significant health concern with limited treatment options.
- Stereotactic body radiation therapy (SBRT) is a localized treatment for various cancers.
- Improving radiation dose delivery and patient outcomes in inoperable pancreatic cancer remains a challenge.
Purpose of the Study:
- To evaluate the safety and potential efficacy of combining avasopasem manganese with SBRT.
- To explore the feasibility of delivering higher than standard radiation doses in patients with pancreatic adenocarcinoma.
Main Methods:
- Phase Ib/II clinical trial.
- Patients with nonmetastatic, inoperable pancreatic adenocarcinoma received SBRT.
- Avasopasem manganese, a superoxide dismutase mimetic, was administered concurrently.
Main Results:
- The combination therapy was found to be potentially safe.
- Preliminary findings suggest improved patient outcomes.
- Higher than standard radiation doses may be safely delivered.
Conclusions:
- Combining avasopasem manganese with SBRT shows promise for treating pancreatic cancer.
- Further investigation in larger trials is warranted to confirm efficacy and compare outcomes.
